SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities and Exchange Act of 1934

(Amendment No. 3)

MERGE HEALTHCARE INCORPORATED

(Name of Issuer)

 

Common Stock, par value $0.01 per share

(Title of Class of Securities)

 

589499102

(CUSIP Number)

 

(Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications)

 

December 4, 2008

(Date of Event Which Requires Filing of this Statement)

 

If the person filing has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 589499102

---

 

Merrick RIS, LLC (26-2506936)

---

---

 

---

 

WC

---

 

---

 

Delaware

---

---

27,618,537

---

 

---

 

49.515%

---

 

OO

 

CUSIP No. 922281100

---

 

Michael W. Ferro, Jr.

---

---

 

---

 

PF

---

 

---

 

USA

---

---

 

27,618,537

---

 

---

 

49.515%

---

 

IN

 

            The following constitutes Amendment No. 3 (“Amendment No. 3”) to the Schedule 13D (the original Schedule 13D, as amended prior to the date hereof, is referred to herein as the “Schedule 13D”) filed by the undersigned with the Securities and Exchange Commission (the “SEC”) on June 16, 2008. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms as set forth in the Schedule 13D.

Amendment No. 3 is being filed to report the entry by RIS into a written plan established pursuant to Rule 10b5-1 under the Act, the acquisition of additional shares of Common Stock of the Company by RIS pursuant to written plans established pursuant to Rule 10b5-1 under the Act and the acquisition of additional shares of Common Stock of the Company by RIS in accordance with all applicable securities laws.

As of the opening of trading on the filing date of this Amendment No. 3, the Reporting Persons, individually and in the aggregate, beneficially own 27,618,537 shares of Common Stock. Since the date of Amendment No. 2, RIS has directly acquired 564,900 shares of Common Stock on the dates and at the prices set forth below:

 

 

 

RIS purchased these shares with funds from equity contributed from its members.

In addition, on November 14, 2008, RIS entered into a plan, in accordance with Rule 10b5-1 of the Act, to acquire up to an additional 300,000 shares of Common Stock, depending on certain market conditions. As of the opening of trading on the date of this Amendment 3, the Reporting Persons have acquired 150,000 shares of Common Stock of the Company pursuant to such written plan.

In addition, on December 5, 2008, RIS entered into a plan, in accordance with Rule 10b5-1 of the Act, to acquire up to an additional 5,000,000 shares of Common Stock, depending on certain market conditions. As of the date hereof, no shares of Common Stock of the Company have been acquired pursuant to such written plan.

Item 5 (a), (b), and (c) of the Schedule 13D are hereby amended and restated as follows:

(a), (b) As of the opening of trading on the date this Amendment 3 is filed, RIS directly owns 27,618,537 shares of Common Stock, which represents 49.515% of the Company’s total Common Stock outstanding. RIS has sole voting and dispositive power over the shares of Common Stock it owns. Ferro is deemed to have sole voting and dispositive power over the shares of Common Stock owned by RIS, which represents 49.515% of the Company’s total Common Stock outstanding. Ferro does not directly own any shares of Common Stock. This Schedule 13D is being filed to report the beneficial ownership of shares of Common Stock which Ferro is deemed to own through his control of RIS. Ferro disclaims beneficial ownership of the shares of Common Stock beneficially owned by him, except to the extent of his pecuniary interest in such shares. The ownership percentages are calculated based on 55,777,624 shares of Common Stock as reported by the Company to be outstanding as of November 3, 2008 in its Form 10-Q filed with the SEC on November 10, 2008, which is incorporated herein by reference.

(c) Except for the transactions described above and in Item 4 of Schedule 13D, during the last sixty days there were no transactions in shares of the Common Stock of the Company effected by the Reporting Persons.

 

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.